ABT
Abbott Laboratories
- EBITDA, 2025
- $11.2B
- YoY, 2025
- +11.2%
- 5-year CAGR
- +5.2%
- 10-year CAGR
- +9.9%
EBITDA
EBITDA by fiscal year
| Period | EBITDA | YoY |
|---|---|---|
| 2025 | $11.2B | +11.2% |
| 2024 | $10.0B | +3.3% |
| 2023 | $9.7B | −16.4% |
| 2022 | $11.6B | −2.8% |
| 2021 | $12.0B | +37.8% |
| 2020 | $8.7B | +15.1% |
| 2019 | $7.5B | +8.9% |
| 2018 | $6.9B | +51.1% |
| 2017 | $4.6B | +4.7% |
| 2016 | $4.4B | +0.9% |
| 2015 | $4.3B | +4.6% |
| 2014 | $4.1B | +7.7% |
| 2013 | $3.9B | −7.0% |
| 2012 | $4.1B | −11.4% |
| 2011 | $4.7B | −46.4% |
| 2010 | $8.7B | +4.6% |
| 2009 | $8.3B | +10.5% |
| 2008 | $7.5B | +17.1% |
| 2007 | $6.4B | — |